Stock listing

NASDAQ:NKTX Nkarta, Inc. Stock

Home listing (NASDAQ) of Nkarta, Inc.

Follow Nkarta, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NKTX

$1.14 USD -0.01 (-1.3%)

Close on Nov 20, 2026

Past year -34.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.11 – $1.22 USDNov 20, 2026
Volume
1.60M sharesNov 20, 2026
Market cap
$81.38M USDAt the close on Nov 20, 2026 · price × 71.70M shares outstanding
52-week range
$1.11 – $3.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.01M USDMedian day 781,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Nkarta, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NKTX · Home$1.135 USD-0.015 (-1.3%)1,603,335$1.12$1.215$1.11$1.15Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NKTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.135-0.015-1.3%$1.12$1.215$1.111,603,335
$1.15-0.10-8.0%$1.25$1.279$1.15811,000
$1.25+0.04+3.3%$1.22$1.28$1.151,043,829
$1.21+0.02+1.7%$1.20$1.28$1.195969,280
$1.19-0.075-5.9%$1.28$1.306$1.1051,406,689
$1.265-0.215-14.5%$1.43$1.43$1.261,021,965
$1.48+0.13+9.6%$1.41$1.51$1.321,153,285
$1.35-0.24-15.1%$1.53$1.54$1.301,213,659
$1.59-0.14-8.1%$1.40$1.60$1.139,298,669
$1.73+0.16+10.2%$1.61$1.84$1.611,973,284
$1.57-0.16-9.2%$1.70$1.72$1.5651,115,697
$1.73+0.20+13.1%$1.58$1.745$1.561,842,404
$1.53+0.01+0.7%$1.54$1.595$1.52726,314
$1.52-0.04-2.6%$1.61$1.63$1.481,394,351
$1.56-0.10-6.0%$1.66$1.66$1.541,211,807
$1.66-0.06-3.5%$1.74$1.76$1.65804,985
$1.72+0.02+1.2%$1.67$1.73$1.631,049,513
$1.70-0.13-7.1%$1.79$1.80$1.582,523,106
$1.83+0.04+2.2%$1.81$1.875$1.7451,152,068
$1.79+0.05+2.9%$1.74$1.81$1.66959,200
$1.74-0.01-0.6%$1.75$1.81$1.721,679,800
$1.75+0.01+0.6%$1.76$1.819$1.741,087,400
$1.74-0.01-0.6%$1.76$1.82$1.741,143,700
$1.75-0.05-2.8%$1.84$1.85$1.751,436,700
$1.80-0.13-6.7%$1.93$1.94$1.781,754,600
$1.93-0.10-4.9%$2.05$2.07$1.911,476,800
$2.03-0.07-3.3%$2.08$2.11$2.02702,300
$2.10-0.07-3.2%$2.15$2.18$2.05790,600
$2.17-0.08-3.6%$2.25$2.275$2.14598,400
$2.25+0.03+1.4%$2.23$2.307$2.14904,900
$2.22-0.05-2.2%$2.25$2.26$2.16720,200
$2.27-0.04-1.7%$2.26$2.335$2.25566,500
$2.31-0.22-8.7%$2.55$2.55$2.295754,600
$2.53-0.045-1.7%$2.57$2.57$2.45522,100
$2.575+0.015+0.6%$2.60$2.625$2.52366,800
$2.56-0.06-2.3%$2.59$2.67$2.545402,300
$2.620.000.0%$2.65$2.69$2.55283,200
$2.62-0.05-1.9%$2.68$2.68$2.53524,600
$2.67-0.08-2.9%$2.75$2.785$2.67810,700
$2.75-0.10-3.5%$2.86$2.86$2.725681,100
$2.85+0.09+3.3%$2.72$2.89$2.585933,800
$2.76-0.19-6.4%$2.91$2.99$2.6151,091,300
$2.95+0.07+2.4%$2.92$2.985$2.865415,600
$2.88+0.05+1.8%$2.87$2.91$2.801385,800
$2.83+0.02+0.7%$2.81$2.885$2.79609,700
$2.81-0.06-2.1%$2.93$2.968$2.745531,400
$2.87-0.01-0.3%$2.93$3.065$2.825642,100
$2.88-0.04-1.4%$2.92$2.95$2.785458,400
$2.92+0.01+0.3%$2.92$3.08$2.865491,100
$2.91+0.10+3.6%$2.85$3.00$2.84486,900
$2.81-0.10-3.4%$2.88$2.88$2.755559,300
$2.91-0.32-9.9%$3.19$3.20$2.86781,600
$3.23+0.31+10.6%$2.86$3.30$2.801,466,400
$2.92+0.13+4.7%$2.77$2.93$2.75447,100
$2.79+0.025+0.9%$2.77$2.885$2.71722,000
$2.765+0.065+2.4%$2.70$2.825$2.655489,600
$2.70-0.01-0.4%$2.62$2.74$2.62570,400
$2.71-0.05-1.8%$2.73$2.75$2.651481,600
$2.76+0.01+0.4%$2.75$2.79$2.695429,800
$2.75+0.12+4.6%$2.63$2.785$2.61538,700
$2.63-0.08-3.0%$2.71$2.71$2.61260,800
$2.71+0.12+4.6%$2.60$2.75$2.575456,530
$2.59-0.07-2.6%$2.63$2.63$2.50449,919
$2.66+0.19+7.7%$2.48$2.735$2.481,107,100
$2.47-0.07-2.8%$2.53$2.54$2.395586,800
Ticker
NASDAQ:NKTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Nkarta, Inc. news

Nkarta, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 96 in all · newest Nov 11, 2026 · oldest 2020
Decks
14 decks · latest Nov 9, 2026

Where Nkarta, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NKTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:NKTXBOATSUnited StatesUSD

Valuation

Price/book 0.4× against a median of 2.3×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$75.22M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.67

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Nkarta, Inc. · NASDAQ:NKTXUS$81.38M−US$75.22Mn/an/an/a0.4×n/a0.0×1.67
Shine-On Biomedical Co., Ltd. · TPEX:6926US$83.59MUS$59.04Mn/a64.8×n/a3.5×−367.6%0.0×n/a
Rallybio Corporation · NASDAQ:RLYBUS$83.29M−US$7.40M3.1×−17.1×n/a0.9×n/a0.0×0.58
TuHURA Biosciences, Inc. · NASDAQ:HURAUS$82.20MUS$89.50Mn/an/an/a4.3×n/a0.5×2.81
3D Medicines, Inc. · HKEX:1244US$81.89MUS$48.39Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Kintor Pharmaceutical Ltd · HKEX:9939US$81.72MUS$96.99Mn/a19.8×n/a5.0×−612.3%1.2×n/a
Captor Therapeutics SA · GPW:CTXUS$81.03MUS$64.09Mn/a130×n/a5.1×n/a0.0×n/a
Vaxart, Inc. · OTC:VXRTUS$79.89MUS$14.34M2.8×0.1×0.4×1.2×16.0%0.0×1.21
Sensorion SAS · EURONEXT:ALSENUS$79.64M−US$13.98Mn/an/an/a0.9×n/a0.0×n/a
Adocia SA · EURONEXT:ADOCUS$79.31MUS$77.84Mn/a48.1×n/an/an/an/an/a
Tiziana Life Sciences Ltd · NASDAQ:TLSAUS$78.98MUS$76.73Mn/an/an/an/an/an/a1.23
Median of the othersUS$81.37MUS$61.57M2.9×19.8×0.4×2.3×−208.7%0.0×1.22

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
10.80 USD · Analysts' mean
EPS, year to Dec 2026
-1.82 · 2 analysts

Team and board

Officers

OfficerRole
Paul HastingsCHIEF EXECUTIVE OFFICER
Nadir MahmoodPRESIDENT
Shawn RoseCHIEF MEDICAL OFFICER AND HEAD OF RESEARCH & DEVELOPMENT

Board

DirectorRole
Ali BehbahaniMember of Board of Directors
Angela ThedingaMember of Board of Directors
George VratsanosMember of Board of Directors
Leone PattersonMember of Board of Directors
Mike DybbsDirector
Paul HastingsCHIEF EXECUTIVE OFFICER
Simeon GeorgeMember of Board of Directors
Zach ScheinerMember of Board of Directors

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+10.2%
Q2 2026Aug 10, 2026 · After close−5.3%
Q1 2026May 13, 2026−14.3%
Q4 2025Mar 25, 2026 · After close+0.5%
Q3 2025Nov 10, 2025 · After close+2.5%
Q2 2025Aug 12, 2025 · After close+12.8%
Q1 2025May 14, 2025 · After close−8.0%
Q4 2024Mar 19, 2025 · Before open−0.7%
Q3 2024Nov 7, 2024 · After close−2.5%
Q2 2024Aug 13, 2024 · After close+3.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−0.8%
Q4 2023Mar 21, 2024 · After close−31.3%
Q3 2023Nov 9, 2023 · After close−1.0%
Q2 2023Aug 10, 2023 · Before open+1.5%
Q1 2023May 11, 2023 · After close+0.5%
Q4 2022Mar 16, 2023 · After close+2.4%
Q3 2022Nov 9, 2022 · After close−2.3%
Q2 2022Aug 11, 2022 · After close+11.3%
Q1 2022May 12, 2022 · After close+10.6%
Q4 2021Mar 17, 2022 · After close+5.0%

Open Events

Decks

DeckKindSlidesDate
ACR Convergence 2026Conference28 slidesNov 9, 2026
Investor Presentation (May 2026)Investor deck21 slidesMay 2026
Investor Presentation (March 2024)Investor deck27 slidesMar 25, 2024
Investor Presentation (January 2024)Investor deck24 slidesJan 8, 2024
Technical Presentation (June 2023)Technical19 slidesJun 27, 2023
EHA 2023Conference15 slidesJun 10, 2023
Corporate Update (December 2022)Corporate update19 slidesDec 5, 2022
Corporate Update (April 2022)Corporate update26 slidesApr 25, 2022
Investor Presentation (October 2021)Investor deck32 slidesOctober 2021
Investor Presentation (July 2021)Investor deck33 slidesJuly 2021
All 14 decks
DeckKindSlidesDate
Investor Presentation (June 2021)Investor deck32 slidesJune 2021
Investor Presentation (May 2021)Investor deck32 slidesMay 2021
Investor Presentation (April 2021)Investor deck30 slidesApril 2021
Investor Presentation (November 2020)Investor deck28 slidesNovember 2020

Open Decks

IPO

Priced at US$18.00 a share on Jul 9, 2020.

Price
US$18.00 a share
Shares offered
14,000,000 shares of common stock
Offering size
US$252 million
Underwriters
Cowen, Evercore ISI, Stifel, Mizuho Securities · In the order on the cover
Shares delivered
On or about Jul 14, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 28, 2020
Filed publiclyJun 19, 2020
Amended 3 timesNewest Jul 9, 2020
Shares registered with an exchangeJul 2, 2020
Declared effective by the SECJul 9, 2020
Final prospectus, with the priceJul 13, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 13, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue00115.0K
Research and development90.4M96.7M96.8M90.9M63.4M36.2M17.2M
Operating income-122.0M-128.2M-131.7M-119.0M-86.4M-51.5M-22.3M
Depreciation and amortization9.20M9.20M5.90M2.60M1.80M800.0K400.0K
EBITDA-112.8M-119.0M-125.8M-116.4M-84.6M-50.7M-21.9M
Income tax0000000
Net income-104.1M-108.8M-117.5M-113.8M-86.1M-91.4M-21.1M
Earnings per share, basic-1.41-1.60-2.40-2.61-2.62-5.44-14.41
Earnings per share, diluted-1.41-1.60-2.40-2.61-2.62-5.44-14.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents39.6M27.9M31.0M37.5M60.8M96.7M20.6M
Short-term investments236.6M239.5M217.1M314.6M177.3M218.2M16.4M
Current assets282.5M273.3M253.1M360.7M245.8M318.8M37.5M
Property, plant and equipment66.7M74.7M79.3M61.9M12.9M9.35M3.08M
Total assets404.2M501.2M378.9M472.9M273.9M337.6M48.4M
Accounts payable2.09M638.0K3.67M1.76M1.11M1.18M1.88M
Current liabilities22.3M18.9M23.3M22.0M12.9M8.83M8.16M
Total liabilities91.9M93.2M105.6M100.7M22.9M16.4M14.1M
Shareholders' equity312.3M408.0M273.3M372.2M251.0M321.2M-25.5M
Shares outstanding71.1M70.6M49.2M48.9M33.0M32.6M1.60M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-88.7M-99.7M-86.2M-57.0M-67.9M-43.5M-18.4M
Capital spending-1.21M-4.41M-28.1M-47.1M-5.03M-7.51M-1.93M
Free cash flow-89.9M-104.1M-114.3M-104.1M-73.0M-51.0M-20.3M
Cash from investing100.3M-129.6M79.0M-184.7M32.5M-210.1M-18.3M
Cash from financing141.0K226.1M691.0K219.0M1.20M329.8M49.6M
Change in cash11.8M-3.17M-6.45M-22.7M-34.2M76.2M12.9M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportNov 6, 2026Current reportSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 19, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
424B5 · ProspectusApr 3, 2026Offer documentSEC
CORRESP · Letter to the SECApr 1, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 31, 2026Other filingsSEC
8-K · Current reportMar 25, 2026Current reportSEC
S-3 · Registration statementMar 25, 2026Offer documentSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
8-K · Current reportMar 25, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 5, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 24, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Management or board changeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 21, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
10-K · Annual reportMar 26, 2025Annual reportSEC
8-K · Current reportMar 26, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 27, 2025Big-stake noticeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJan 2, 2025Offer documentSEC
SC 13G · Big-stake noticeDec 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedOct 25, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
8-K/A · Current report, amendedAug 15, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024Material contractSEC
4 · Change in ownershipJul 31, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 31, 2024Insider tradeSEC
4 · Change in ownershipJul 31, 2024Insider tradeSEC
4 · Change in ownershipJul 18, 2024Insider tradeSEC
144 · Notice of proposed saleJul 16, 2024Other filingsSEC
8-K · Current reportJul 16, 2024Management or board changeSEC
8-K · Current reportJun 27, 2024Current reportSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 15, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 5, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 29, 2024Big-stake noticeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMar 29, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 28, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 28, 2024Big-stake noticeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
8-K · Current reportMar 28, 2024Current reportSEC
424B5 · ProspectusMar 25, 2024Offer documentSEC
8-K · Current reportMar 25, 2024Current reportSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
144 · Notice of proposed saleMar 4, 2024Other filingsSEC
144 · Notice of proposed saleMar 1, 2024Other filingsSEC
144 · Notice of proposed saleMar 1, 2024Other filingsSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 12, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2024Big-stake noticeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 18, 2024Insider tradeSEC
SC 13G · Big-stake noticeJan 18, 2024Big-stake noticeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
8-K · Current reportJan 8, 2024Current reportSEC
S-8 · Registration statement for employee plansJan 3, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
SC 13G · Big-stake noticeNov 3, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeOct 27, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeOct 26, 2023Big-stake noticeSEC
8-K · Current reportOct 17, 2023ResultsSEC
8-K · Current reportOct 16, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 10, 2023Big-stake noticeSEC
4 · Change in ownershipAug 23, 2023Insider tradeSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 5, 2023Insider tradeSEC
8-K · Current reportJul 5, 2023Management or board changeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
8-K · Current reportJun 27, 2023Current reportSEC
8-K · Current reportJun 26, 2023Current reportSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 22, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
8-K · Current reportJun 9, 2023Meeting outcomeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedMay 10, 2023Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 8, 2023Other filingsSEC
CORRESP · Letter to the SECMay 3, 2023Other filingsSEC
S-3/A · Registration statement, amendedApr 24, 2023Offer documentSEC
ARS · Annual report to shareholdersApr 24, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2023Meeting noticeSEC

This page holds 200 of 440 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Nkarta, Inc.’s releases · as of Nov 2, 2026

Common shares
71,704,404
Fully diluted
71,704,404

Fully diluted

LineSharesAs of
Common shares71,704,404Nov 2, 2026

Share count over time

CountShares
Nov 2, 202671,704,404

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Ra Capital Management, L.P.10.8M15.1%US$28.3MNo changeNov 16, 2026
BlackRock6.85M9.5%US$17.9M+547KNov 13, 2026
NEA Management Company, LLC3.57M5.0%US$9.35MNo changeNov 16, 2026
Samsara Biocapital, LLC3.51M4.9%US$9.19MNo changeNov 16, 2026
Sr One Capital Management, LP3.33M4.6%US$8.73MNo changeNov 16, 2026
GSK plc3.15M4.4%US$8.25MNo changeNov 5, 2026
Vanguard3.1M4.3%US$8.13M+187KNov 16, 2026
Monaco Asset Management SAM2.19M3.0%US$5.73M−188KNov 9, 2026
Acadian Asset Management LLC1.73M2.4%US$4.52M+368KNov 9, 2026
Citadel1.7M2.4%US$4.45M−476KNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Two Sigma1.69M2.4%US$4.42M−185KNov 16, 2026
Wasatch Advisors LP1.67M2.3%US$4.37M+88,749Oct 13, 2026
AQR Capital Management LLC1.4M2.0%US$3.67M+346KNov 16, 2026
State Street1.32M1.8%US$3.46M+34,818Nov 12, 2026
Geode Capital1.31M1.8%US$3.44M+28,144Nov 6, 2026
Alyeska Investment Group, L.P.985K1.4%US$2.58M+500KNov 16, 2026
AWM Investment Company, Inc.906K1.3%US$2.37MNo changeNov 13, 2026
Renaissance Technologies799K1.1%US$2.09M−378KNov 12, 2026
Blackstone Inc.747K1.0%US$1.96MNo changeNov 16, 2026
Panagora Asset Management Inc663K0.93%US$1.74M+80,248Nov 12, 2026
Marshall Wace, LLP612K0.85%US$1.6M−60,952Nov 13, 2026
JPMorgan558K0.78%US$1.46M−5,188Nov 12, 2026
Peapod Lane Capital LLC518K0.72%US$1.36M−31,517Oct 22, 2026
Dimensional511K0.71%US$1.34M+27,404Nov 4, 2026
Northern Trust383K0.53%US$1M+11,403Nov 16, 2026
Morgan Stanley350K0.49%US$917K+86,149Nov 13, 2026
Goldman Sachs348K0.48%US$911K−86,428Nov 16, 2026
Susquehanna243K0.34%US$635K+38,733Nov 16, 2026
D. E. Shaw & Co., Inc.238K0.33%US$623K+75,344Nov 16, 2026
XTX Topco Ltd232K0.32%US$608K−57,961Nov 16, 2026
Millennium215K0.30%US$563K−109KNov 16, 2026
Invesco205K0.29%US$536K−2,772Nov 12, 2026
Qube Research & Technologies Ltd195K0.27%US$511K+74,168Nov 13, 2026
Man Group plc149K0.21%US$391K+49,212Nov 16, 2026
Fidelity145K0.20%US$379K+14,882Nov 10, 2026
Los Angeles Capital Management LLC143K0.20%US$374K+102KNov 12, 2026
Nano Cap New Millennium Growth Fund L P140K0.20%US$367K+10,000Nov 13, 2026
Point72 Asset Management, L.P.137K0.19%US$359K+30,248Nov 16, 2026
Schwab133K0.19%US$348K+1,793Nov 16, 2026
Barclays132K0.18%US$346K+10,648Nov 6, 2026
Gsa Capital Partners LLP128K0.18%US$335K+14,359Nov 16, 2026
Nuveen125K0.17%US$327K−345KNov 10, 2026
Bridgeway Capital Management, LLC121K0.17%US$317K−1,835Nov 16, 2026
BNY118K0.16%US$309K+2,964Nov 5, 2026
Empowered Funds, LLC108K0.15%US$283K+38,523Nov 13, 2026
AllianceBernstein101K0.14%US$264KNo changeNov 16, 2026
American Century94,8510.13%US$249KNo changeNov 20, 2026
WINTON GROUP Ltd91,0980.13%US$239K+75,298Nov 12, 2026
Stifel Financial Corp80,1720.11%US$210K+9,140Nov 12, 2026
CPP Investments74,4000.10%US$195K+45,700Nov 16, 2026

This page holds 50 of 117 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund1.57M2.2%US$4.43M+151KJun 30, 2026
Wasatch Ultra Growth Fund1.49M2.1%US$4.21MNo changeJun 30, 2026
iShares Russell 2000 ETF1.14M1.6%US$3.24M+37,484Jun 30, 2026
Vanguard Extended Market Index Fund573K0.80%US$1.62M+15,684Jun 30, 2026
Fidelity Small Cap Index Fund490K0.68%US$1.02M+30,110Jul 31, 2026
iShares Russell 2000 Value ETF455K0.63%US$1.29M+37,897Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account350K0.49%US$989KNo changeJun 30, 2026
Fidelity Extended Market Index Fund283K0.39%US$919K+4,647May 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.266K0.37%US$753KNewJun 30, 2026
BlackRock Advantage Small Cap Growth Fund264K0.37%US$747KNewJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Russell 2000 Index Fund238K0.33%US$775K+28,351May 31, 2026
iShares Micro-Cap ETF150K0.21%US$425K+32,404Jun 30, 2026
Dimensional U.S. Small Cap ETF145K0.20%US$304K+7,873Jul 31, 2026
Ultra-Small Company Market Fund110K0.15%US$311K+15,000Jun 30, 2026
Schwab Small-Cap Index Fund108K0.15%US$227KNo changeJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF103K0.14%US$215K−39,342Jul 31, 2026
Avantis U.S. Small Cap Equity ETF90,2670.13%US$293KNo changeMay 31, 2026
Master Small Cap Index Series86,1640.12%US$244KNo changeJun 30, 2026
Fidelity Total Market Index Fund84,0270.12%US$273KNo changeMay 31, 2026
Sequoia Global Value ETF80,0980.11%US$227KNewMay 29, 2026
Fidelity Series Total Market Index Fund77,7620.11%US$253K+7,113May 31, 2026
BlackRock Advantage SMID Cap Fund, Inc.67,7340.09%US$192KNewJun 30, 2026
U.S. Micro Cap Portfolio63,1710.09%US$132K+29,565Jul 31, 2026
Fidelity Small Cap Value Index Fund62,8040.09%US$178K+5,084Jun 30, 2026
Nuveen Small Cap Blend Index Fund60,3830.08%US$126K+23,757Jul 31, 2026
Wasatch Long/Short Alpha Fund57,4410.08%US$163KNo changeJun 30, 2026
EQ/2000 Managed Volatility Portfolio55,8300.08%US$158K+22,312Jun 30, 2026
EQ/Small Company Index Portfolio54,0400.08%US$153K+5,540Jun 30, 2026
Diversified Equity Alpha Master Portfolio52,7300.07%US$149KNewJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund49,3600.07%US$140K+16,939Jun 30, 2026
U.S. Small Cap Portfolio47,7670.07%US$99,833+6,300Jul 31, 2026
Fidelity Nasdaq Composite Index Fund44,4700.06%US$145KNo changeMay 31, 2026
VIP Disciplined Small Cap Portfolio42,6060.06%US$121KNo changeJun 30, 2026
EQ/AB Small Cap Growth Portfolio38,8900.05%US$110K+5,540Jun 30, 2026
Vanguard Russell 2000 Value Index Fund37,9020.05%US$123K+6,297May 31, 2026
LVIP State Street Small-Cap Index Fund35,3000.05%US$99,899No changeJun 30, 2026
Nuveen Equity Index Fund34,8400.05%US$72,816No changeJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund32,8450.05%US$92,951NewJun 30, 2026
BlackRock Advantage SMID Cap V.I. Fund29,8110.04%US$84,365NewJun 30, 2026
Fidelity ZERO Total Market Index Fund28,9500.04%US$60,506−2,424Jul 31, 2026
Vanguard Balanced Index Fund27,0220.04%US$76,472−11,049Jun 30, 2026
AVIP BlackRock Advantage Small Cap Growth Portfolio25,6720.04%US$72,652+18,513Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund24,3950.03%US$69,038No changeJun 30, 2026
Small Cap Index Fund22,6210.03%US$73,518No changeMay 31, 2026
U.S. Vector Equity Portfolio22,5430.03%US$47,115NewJul 31, 2026
Small Cap Index Fund22,5260.03%US$63,749−3,654Jun 30, 2026
Schwab Total Stock Market Index Fund22,4780.03%US$46,979No changeJul 31, 2026
Global X Russell 2000 ETF21,3360.03%US$44,592+2,061Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio19,1340.03%US$54,149+4,562Jun 30, 2026
Fidelity ZERO Extended Market Index Fund19,0980.03%US$39,915−757Jul 31, 2026

This page holds 50 of 116 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Hastings Paul J
Director, Officer: Chief Executive Officer
Sale1,776USD 2.71US$4,813Jun 18, 2026

Big stakes

HolderStakeSharesDate
New Enterprise Associates 15, L.P.4.90%3.57MMay 19, 2026
Samsara BioCapital, L.P.4.90%3.51MNov 20, 2025
LSP 6 Holding C.V.2.00%1.42MFeb 12, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Kolchinsky
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past)
Director · Since at least Feb 14, 2022
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Feb 14, 2022
Ali Behbahani
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Black Diamond Therapeutics, Inc. (Co-Head of Healthcare, NEA · Since at least Jan 29, 2020); CRISPR Therapeutics AG (Director · Since at least Oct 18, 2016); Adaptimmune Therapeutics PLC (Director · Since at least Jan 1, 2016); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past); Marker Therapeutics, Inc. (Director · Oct 17, 2018 – Oct 17, 2018 · Past); Nevro Corp (Director · Nov 5, 2014 – May 21, 2018 · Past)
Member of Board of Directors · Since at least Jul 9, 2020
Leone Patterson
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Climb Bio, Inc. (Director · Aug 9, 2021 – May 19, 2022 · Past); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Jul 29, 2021 – Feb 23, 2024 · Past); Adverum Biotechnologies Inc (President and CFO · Jun 15, 2016 – Feb 16, 2021 · Past); Paratek Pharmaceuticals Inc (Vice President, CFO · Jun 25, 2012 – Oct 30, 2014 · Past)
Member of Board of Directors · Since at least Jul 9, 2020
Paul Hastings
Other companies: enGene Therapeutics Inc. (Director · Since at least May 15, 2024); Protara Therapeutics, Inc. (Director · Oct 18, 2016 – Jun 8, 2018 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); OncoMed Pharmaceuticals Inc (Chairman & CEO · Jul 17, 2013 – Oct 10, 2017 · Past); Pacira BioSciences, Inc. (Director · Jun 2, 2011 – Jun 12, 2024 · Past)
CHIEF EXECUTIVE OFFICER · Since at least Jul 9, 2020
Simeon George
Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); CRISPR Therapeutics AG (Director · Since at least Oct 18, 2016); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Aug 17, 2022 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 28, 2020 · Past)
Member of Board of Directors · Since at least Jul 9, 2020
Michael Dybbs
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past)
Director · Since at least Jul 9, 2020
Tiba Aynechi
Other companies: MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); iRhythm Holdings, Inc. (Director · Oct 19, 2016 – Apr 7, 2017 · Past)
Director · Jul 9, 2020 – Jun 8, 2022 · Past
Laura Shawver
Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020); Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jun 3, 2024 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past)
Director · Jul 9, 2020 – Jun 8, 2022 · Past
Kanya Rajangam
Other companies: Senti Biosciences Holdings, Inc. (Pres. & Chief Med. & Dev. Off. · Since at least Jul 5, 2022); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jun 3, 2024 · Past)
Chief Medical Officer · Jul 9, 2020 – Jan 14, 2022 · Past
All 23 people
PersonSeat
Matthew Plunkett
Other companies: Imago Biosciences Inc (Chief Financial Officer · Jul 15, 2021 – Jul 15, 2021 · Past); CTi Biopharma Corp (EVP, Chief Business Officer, Director · Sep 4, 2012 – Mar 1, 2017 · Past)
Chief Financial Officer · Jul 9, 2020 – Jul 9, 2020 · Past
Zach Scheiner
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024)
Member of Board of Directors · Since at least Jul 9, 2020
Alicia J Hager
Other companies: OncoMed Pharmaceuticals Inc (SVP and General Counsel · Oct 7, 2017 – Apr 23, 2019 · Past)
Chief Legal Officer · Oct 26, 2020 – Jan 15, 2025 · Past
Angela Thedinga
Other companies: Adverum Biotechnologies Inc (Chief Technology Officer · Feb 21, 2020 – Aug 6, 2021 · Past)
Member of Board of Directors · Since at least Mar 28, 2022
David Shook
Other companies: Lyell Immunopharma, Inc. (Chief Medical Officer · Since at least Jun 9, 2025)
See Remarks · Jan 1, 2023 – Jan 15, 2025 · Past
Mike Dybbs
Other companies: Kalaris Therapeutics, Inc. (Director & Co-founder · Since at least Nov 8, 2024)
Director · Since at least Nov 4, 2026
Alyssa LevinSee Remarks · Jul 1, 2023 – Jan 15, 2025 · Past
Fouad Oscar AzzamDirector · Jul 9, 2020 – Jun 7, 2023 · Past
George VratsanosMember of Board of Directors · Since at least Jun 13, 2024
James TragerChief Scientific Officer · Jul 9, 2020 – Jun 18, 2024 · Past
Nadir MahmoodPresident · Since at least Jul 9, 2020
Ralph BrandenbergerChief Technical Officer · Mar 24, 2021 – Jan 15, 2025 · Past
Shawn RoseCHIEF MEDICAL OFFICER AND HEAD OF RESEARCH & DEVELOPMENT · Since at least Jun 6, 2025

Open People

Log in to ask 6ix AI your own questions about Nkarta, Inc.